NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...

Core Viewpoint - Investors in Kyverna Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred following the company's initial public offering in February 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Kyverna Therapeutics failed to disclose adverse data related to one of its clinical trials, which misled investors regarding the company's business and operational prospects [3]. - The complaint highlights that the defendants' positive statements about the company's performance lacked a reasonable basis due to the withholding of critical adverse data [3]. Group 2: Participation Information - Investors who suffered losses in Kyverna Therapeutics are encouraged to contact the Law Offices of Howard G. Smith before February 7, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the law firm via email or phone [4][5].

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=120456&from=4CLASS PERIOD: Th ...

Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. for allegedly making false or misleading statements in its IPO prospectus, particularly regarding adverse clinical trial data [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Kyverna common stock during its IPO on February 8, 2024, with a lead plaintiff deadline set for February 7, 2025 [1]. - The complaint claims that Kyverna's prospectus contained materially false and misleading statements about the company's business and operations, specifically omitting adverse data from a clinical trial at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by February 7, 2025, or may choose to remain absent from the class [3]. - The lead plaintiff will represent all class members and select counsel to direct the litigation, with the ability to recover not affected by the decision to serve as lead plaintiff [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging Kyverna investors who have experienced significant losses to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=118959&from=4 CLASS PERIOD: ...

Core Viewpoint - The Kyverna class action lawsuit alleges that the company's IPO offering documents were materially false and misleading, failing to disclose adverse data related to clinical trials, which negatively impacted the company's future operating results and share price [2][8]. Group 1: Lawsuit Details - The lawsuit, titled Rondini v. Kyverna Therapeutics, Inc., charges Kyverna and certain executives and underwriters with violations of the Securities Act of 1933 [6]. - Investors who purchased or acquired Kyverna common stock during the IPO, which took place on February 8, 2024, have until February 7, 2025, to seek appointment as lead plaintiff [6]. - The IPO involved the offering of 14.5 million shares at a price of $22.00 per share, resulting in net proceeds of approximately $296 million for Kyverna [7]. Group 2: Impact of Adverse Data - On June 14, 2024, Kyverna disclosed adverse data regarding one of its clinical trials, leading to a significant decline in share price [8]. - By the time the class action lawsuit commenced, Kyverna's stock had fallen to as low as $3.92, representing a decline of over 82% from the IPO price [8].

RADNOR, Pa., Dec. 27, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Kyverna losses, you ...

Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. alleging false statements and omissions related to its initial public offering (IPO) [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the IPO strategy, terms, and disclosures in the Offering Documents [2]. - It is alleged that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal team [2]. Group 2: Class Definition and Participation - The lawsuit aims to recover losses for investors who purchased Kyverna common stock linked to the company's February 2024 IPO [4]. - Investors affected by the alleged securities fraud can participate without incurring out-of-pocket costs [3]. Group 3: Next Steps for Investors - Investors who suffered losses in Kyverna Therapeutics have until February 7, 2025, to request to be appointed as lead plaintiff [5]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [6].

SAN DIEGO, Dec. 26, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.For more in ...